Lee Shapiro - Concepedia

Author

Lee Shapiro

Also Known As

L S Shapiro, L Shapiro, L. S. Shapiro, L. Shapiro, LEE SHAPIRO, Lee S Shapiro, Lee S. Shapiro, Lee Shapiro, Lesley Saketkoo, Michelle Richard

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Johns Hopkins University Albany Medical Center Hospital University of Colorado Denver University of Michigan University of Pennsylvania

About

Lee Shapiro is an author at Johns Hopkins University specializing in medicine, cardiovascular disease, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	533
2	Public Health	4	4	212
3	Health Sciences	1	1	21
4	Allergy	1	1	21
5	Cardiothoracic Surgery	1	1	16

Lee Shapiro

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Survival and Predictors of Mortality in Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry Robyn T. Domsic, Bharathi Lingala, Firas Alkassab, Arthritis Care & Research	2013	168
Accelerated clearance of small solutes from the lungs in interstitial lung disease. Jeannine D. Rinderknecht, Lee Shapiro, M Krauthammer, PubMed 99Mtc-dtpa ClearanceInflammatory Lung DiseaseAdvanced Lung DiseaseLung InflammationImmunology	1980	165
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases Sindhu R. Johnson, Elana J. Bernstein, Marcy B. Bolster, Arthritis & Rheumatology	2024	130
MQX‐503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: A randomized, controlled trial Lee Shapiro, David Fiorentino, Murray Baron, Arthritis & Rheumatism	2009	108
Degos Disease Cynthia M. Magro, Jonathan C. Poe, Connie Kim, American Journal of Clinical Pathology Degos DiseaseVasculitisImmunodeficienciesImmune RegulationImmunology	2011	108
Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS) Kathleen D. Kolstad, Shufeng Li, Virginia Steen, CHEST Journal HypertensionPulmonary Arterial HypertensionCardiovascular DiseaseSystemic SclerodermaPulmonary Hypertension Assessment	2018	100
2023 American College of Rheumatology (<scp>ACR</scp>)/American College of Chest Physicians (<scp>CHEST</scp>) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases Sindhu R. Johnson, Elana J. Bernstein, Marcy B. Bolster, Arthritis & Rheumatology	2024	99
Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study Vivien Hsu, Laura K. Hummers, Fredrick M. Wigley, Seminars in Arthritis and Rheumatism HypertensionPulmonary Arterial HypertensionCardiovascular DiseaseSystemic SclerodermaPulmonary Hypertension Assessment	2014	83
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases Sindhu R. Johnson, Elana J. Bernstein, Marcy B. Bolster, Arthritis Care & Research	2024	81
The effects of Eculizumab on the pathology of malignant atrophic papulosis Cynthia M. Magro, Xuan Wang, Francine E. Garrett-Bakelman, Orphanet Journal of Rare Diseases	2013	67

Page 1